Search

Your search keyword '"Boissel, Nicolas"' showing total 1,214 results

Search Constraints

Start Over You searched for: Author "Boissel, Nicolas" Remove constraint Author: "Boissel, Nicolas"
1,214 results on '"Boissel, Nicolas"'

Search Results

1. Acute lymphoblastic leukaemia

3. Inotuzumab Ozogamicin and Low-Intensity Chemotherapy in Older Patients With Newly Diagnosed CD22+ Philadelphia Chromosome–Negative B-Cell Precursor Acute Lymphoblastic Leukemia

4. Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3.

5. Early lymphocyte reconstitution and viral infections in adolescents and adults transplanted for sickle cell disease

7. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients

8. Genomic imbalance analysis provides new insight into prognostic factors in adult and pediatric T-ALL

9. Nilotinib with or without cytarabine for Philadelphia-positive acute lymphoblastic leukemia

10. TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2

11. Harnessing the MYB-dependent TAL1 5’super-enhancer for targeted therapy in T-ALL

13. Two-year follow-up of KTE-X19 in patients with relapsed or refractory adult B-cell acute lymphoblastic leukemia in ZUMA-3 and its contextualization with SCHOLAR-3, an external historical control study

15. Genetic alterations and MRD refine risk assessment for KMT2A-rearranged B-cell precursor ALL in adults: a GRAALL study

16. Combining blinatumomab and donor lymphocyte infusion in B-ALL patients relapsing after allogeneic hematopoietic cell transplantation: a study of the SFGM-TC

17. IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition

20. Long-term survival outcomes of patients (pts) with relapsed or refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) treated with brexucabtagene autoleucel (brexu-cel) in ZUMA-3.

21. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial

22. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL

23. The use of ICU resources in CAR-T cell recipients: a hospital-wide study

26. Inotuzumab ozogamicin in adult acute lymphoblastic leukemia: Development, current status, and future directions.

27. Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia

28. Early detection of WT1 measurable residual disease identifies high-risk patients, independent of transplantation in AML

30. DESCAR-T, le registre national des patients traités par CAR-T Cells

31. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study

32. A multiparametric niche-like drug screening platform in acute myeloid leukemia

33. Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study

35. COVID19 and acute lymphoblastic leukemias of children and adolescents: Updated recommendations (Version 2) of the Leukemia Committee of the French Society for the fight against Cancers and leukemias in children and adolescents (SFCE)

36. Efficacy and tolerance of brexucabtagene autoleucel in adults with R/R B-ALL: a GRAALL study from the DESCAR-T registry

38. A personalized approach to guide allogeneic stem cell transplantation in younger adults with acute myeloid leukemia

39. A transcriptomic continuum of differentiation arrest identifies myeloid interface acute leukemias with poor prognosis

40. Clonal dominance is an adverse prognostic factor in acute myeloid leukemia treated with intensive chemotherapy

41. COVID-19 and acute lymphoblastic leukemias of children and adolescents: First recommendations of the Leukemia committee of the French Society for the fight against Cancers and Leukemias in children and adolescents (SFCE)

42. Added prognostic value of secondary AML-like gene mutations in ELN intermediate-risk older AML: ALFA-1200 study results

43. EHA evaluation of the ESMO—Magnitude of Clinical Benefit Scale version 1.1 (ESMO-MCBS v1.1) for haematological malignancies

44. Management of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

45. Diagnosis, Prognostic Factors and Assessment of ALL in Adults: 2023 ELN Recommendations from a European Expert Panel

46. Supplementary Figure S1 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

47. Supplementary Table S2 from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

48. Data from PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax

50. Clinico-biological features of T-cell acute lymphoblastic leukemia with fusion proteins

Catalog

Books, media, physical & digital resources